U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
SAN DIEGO - Fate Therapeutics Inc. (NASDAQ: FATE), a biopharmaceutical company currently valued at approximately $140 million, announced today that it will present clinical and preclinical data related to its off-the-shelf cellular immunotherapies at the European Congress of Rheumatology (EULAR 2025) in Barcelona, Spain, from June 11-14. The company’s stock has experienced significant volatility, with a 60% decline over the past six months, according to InvestingPro data.
The company’s oral presentation will feature clinical data from the ongoing Phase 1 trial of its product candidate FT819, designed for patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial assesses the safety and activity of FT819, which is a CD19-targeted, 1XX CAR T-cell therapy, in patients who are receiving either a fludarabine-free conditioning regimen or maintenance therapy without conditioning. While the company maintains a strong liquidity position with a current ratio of 8.8, InvestingPro analysis indicates rapid cash burn remains a key challenge.
In addition to the oral presentation, Fate Therapeutics will also showcase poster presentations on its next-generation off-the-shelf CAR T-cells and CAR-NK cell therapy. These presentations will highlight the potential of these therapies to eliminate aberrant effector cells in autoimmune diseases without the need for conditioning chemotherapy and the use of alloimmune defense technology for persistent treatment in autoimmune diseases.
Fate Therapeutics’ iPSC product platform utilizes human induced pluripotent stem cells (iPSCs) to manufacture engineered cell products that are uniform in composition, can be stored for off-the-shelf availability, and administered in combination with other therapies. The platform aims to address limitations associated with patient- and donor-sourced cell therapies and is supported by an extensive intellectual property portfolio.
The news comes as the company continues to develop its pipeline of iPSC-derived T-cell and natural killer (NK) cell product candidates, incorporating novel synthetic controls of cell function to potentially benefit a broad patient population.
The forward-looking statements in the press release reflect management’s current expectations but are subject to risks and uncertainties that could cause actual results to differ materially. These include risks related to clinical development and regulatory approval processes.
The details of the presentations and the accepted abstracts are available on the EULAR 2025 website. This report is based on a press release statement from Fate Therapeutics.
In other recent news, Fate Therapeutics reported financial results for the fourth quarter of 2024, with revenue reaching $1.86 million, surpassing analyst expectations of $1.58 million. The company ended the quarter with $306.7 million in cash, which it expects will support operations through the end of 2026. Fate Therapeutics’ FT819, an off-the-shelf CAR T-cell therapy, received Regenerative Medicine Advanced Therapy designation from the FDA for systemic lupus erythematosus, indicating expedited development and review. The company is also expanding its Phase 1 clinical trial for FT819 and plans to present additional data at upcoming medical conferences. Analyst firms have adjusted their price targets for Fate Therapeutics, with Baird lowering it to $4 while maintaining a Neutral rating, Stifel reducing it to $3 with a Hold rating, and Jefferies setting it at $8 with a Buy rating. These adjustments follow the company’s updates on its clinical programs and management changes, including the appointment of a new CEO. Fate Therapeutics is progressing with its lead product, FT819, and plans to expand clinical sites internationally. The company’s pipeline includes multiple iPSC-derived T-cell and NK cell product candidates, supported by a substantial intellectual property portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.